Author: Jessica Mouzo Quintáns

In just a decade, CAR-T cell therapy has transformed the outlook for individuals with blood cancer by genetically modifying T-lymphocytes to enhance their ability to combat tumors. While the therapy has been effective in treating hematological cancers, its success in solid tumors has been limited. A recent study in Science Advances showcased a new and more potent version of CAR-T, called TOP CAR, which targets the B7-H3 antigen found on tumor cells. This redesigned CAR-T, created by Dr. Xingxing Zang, has shown promising results in animal studies, with improved survival rates in mice with brain, pancreatic, and lung cancers. Zang’s…